Baystate Wealth Management’s Intellia Therapeutics NTLA Stock Holding History

Baystate Wealth Management’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$2.85K	Hold	93	–	–	﹤0.01%	1005
2023 Q3	$2.95K	Hold	93	–	–	﹤0.01%	759
2023 Q2	$3.81K	Hold	93	–	–	﹤0.01%	748
2023 Q1	$3.48K	Hold	93	–	–	﹤0.01%	742
2022 Q4	$3K	Hold	93	–	–	﹤0.01%	748
2022 Q3	$5K	Hold	93	–	–	﹤0.01%	646
2022 Q2	$5K	Hold	93	–	–	﹤0.01%	665
2022 Q1	$7K	Hold	93	–	–	﹤0.01%	624
2021 Q4	$11K	Buy	+93	New	+$11.7K	﹤0.01%	560
2020 Q4	–	Sell	-20	Closed	–	–	735
2020 Q3	$0	Buy	+20	New	+$417	﹤0.01%	710

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Baystate Wealth Management's NTLA Position: Q4 2023 in Review

Baystate Wealth Management held its Intellia Therapeutics (NTLA) position steady in Q4 2023 at 93 shares worth $2.85K. The position accounts for ﹤0.01% of the portfolio, ranked #1005.

Baystate Wealth Management first reported a position in NTLA in Q3 2020 and has held it in 10 quarters since. The position peaked at $11K in Q4 2021. 292 funds tracked by Wall St. Rank hold NTLA as of Q4 2023.

Baystate Wealth Management held 93 shares of Intellia Therapeutics worth $2.85K as of Q4 2023.
Baystate Wealth Management left its Intellia Therapeutics share count unchanged in Q4 2023.
Intellia Therapeutics made up ﹤0.01% of Baystate Wealth Management's portfolio in Q4 2023, its #1005 holding.
Baystate Wealth Management first reported a position in Intellia Therapeutics in Q3 2020 and has held it in 10 quarters since.
Baystate Wealth Management's Intellia Therapeutics position peaked at $11K in Q4 2021.
292 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2023.

Based on Baystate Wealth Management's 13F filing for Q4 2023, filed 29 Jan 2024.